rna
interfer
rnai
process
doublestrand
rna
induc
activ
cellular
pathway
lead
potent
select
silenc
gene
homolog
doubl
strand
much
excit
surround
small
interf
rna
sirna
mediat
therapeut
aris
fact
approach
overcom
mani
shortcom
previous
experienc
approach
antibodi
antisens
oligonucleotid
pharmacolog
inhibitor
induct
rnai
administr
sirna
success
use
treatment
hepat
viral
infect
cancer
review
present
brief
histori
rnai
method
induc
rnai
applic
rnai
therapeut
set
possibl
use
highli
promis
approach
context
transplant
method
manipul
biolog
system
includ
pharmacolog
drug
antisens
oligonucleotid
ao
ribozym
antibodi
transplant
approach
appli
vari
degre
success
revolutionari
discoveri
endogen
cellular
process
rna
interfer
rnai
artifici
manipul
induc
genespecif
silenc
administr
small
interf
rna
sirna
led
explos
interest
techniqu
attract
rnai
contrast
method
manipul
aris
extrem
high
inhibitori
activ
fact
inhibit
specif
eas
variou
method
induc
rnai
appli
owe
explos
interest
sirna
sever
other
review
field
concentr
genet
mechan
rnai
deliveri
methodolog
effect
global
gene
silenc
paper
review
therapeut
aspect
sirna
appli
transplant
research
rna
interfer
endogen
cellular
defenc
mechan
virus
transpos
element
genom
upon
recognit
danger
doublestrand
rna
dsrna
enzymat
complex
degrad
mrna
transcript
homolog
dsrna
impli
artifici
induct
rnai
use
silenc
patholog
gene
therapeut
manner
fact
rnai
natur
defenc
mechan
suggest
manipul
phenomenon
intervent
would
biolog
approach
induc
genet
alter
compar
method
ao
chemic
inhibitor
enzym
initi
suggest
rnai
came
work
petunia
flower
overexpress
gene
respons
purpl
pigment
actual
caus
flower
lose
endogen
colour
phenomenon
term
cosuppress
insert
gene
transcript
endogen
transcript
suppress
mechan
remain
unclear
fire
et
al
found
combin
sens
antisens
rna
led
potent
suppress
gene
express
sens
antisens
use
individu
dsrna
seem
induc
inhibit
pathway
distinct
classic
antisens
inhibit
suppress
effect
observ
use
dsrna
potent
ever
seen
approxim
molecul
duplex
rna
per
cell
effect
knock
gene
express
semin
paper
first
describ
rnai
coin
name
accordingli
despit
potenc
gene
inhibit
initi
descript
rnai
could
use
therapeut
purpos
mammalian
cell
owe
long
dsrna
nucleotid
activ
panic
respons
eukaryot
cell
part
includ
nonspecif
inhibit
gene
transcript
product
interferona
enzym
pkr
oligosynthetas
interact
dsrna
trigger
nonspecif
respons
howev
problem
overcom
discoveri
effector
mechan
geneinhibit
dsrna
demonstr
long
dsrna
duplex
enter
cytoplasm
ribonucleas
iiityp
enzym
term
dicer
cleav
duplex
smaller
basepair
figur
small
duplex
call
sirna
activ
silenc
endogen
produc
mrna
transcript
sirna
homolog
mrna
transcript
enter
cell
mobil
selfaggreg
complex
call
rnainduc
silenc
complex
risc
unwind
sirna
hybrid
mrna
induc
cleavag
mrna
subsequ
continu
perform
process
without
panic
respons
depict
figur
b
administr
preform
sirna
duplex
bypass
nonspecif
activ
pkr
oligosynthetas
allow
genespecif
silenc
stimul
risc
upon
viral
infect
presenc
dsrna
transduct
intracellularli
innat
defens
system
activ
caus
sequenti
degrad
dsrna
type
iii
endonucleas
dicer
endonucleas
subsequ
cleav
dsrna
nucleotid
doublestrand
fragment
fragment
associ
rnainduc
silenc
complex
risc
complex
induc
cleavag
endogen
mrna
transcript
sequenceand
lengthspecif
manner
howev
long
dsrna
also
activ
oligosynthetas
induc
nonspecif
interferon
respons
global
shutdown
protein
synthesi
b
artifici
gene
silenc
sirna
take
advantag
genesilenc
effect
circumv
nonspecif
cellular
effect
synthet
dsrna
nucleotid
transfect
cell
small
interf
rna
sirna
recogn
dicer
oligosynthetas
instead
directli
bind
risc
complex
subsequ
induc
select
silenc
endogen
transcript
discoveri
sirna
effector
mechan
endogen
rnai
prompt
investig
abil
util
exogen
administ
sirna
vector
induc
express
sirna
genespecif
silenc
genet
manipul
use
strategi
rais
sever
issu
need
address
stabil
sirna
abil
constitut
express
sirna
possibl
tissuespecif
deliveri
find
best
method
identifi
effect
silenc
site
mrna
transcript
order
answer
question
variou
version
sirna
develop
chemic
synthesi
oligonucleotid
readili
use
procedur
molecular
biolog
owe
short
size
nucleotid
length
sirna
typic
nucleotid
synthesi
techniqu
use
howev
product
sirna
requir
sever
addit
step
includ
gener
two
homolog
strand
anneal
strand
vitro
addit
chemic
entiti
increas
stabil
ensur
overhang
present
purpos
overhang
activ
rnaiinduc
enzymat
complex
risc
addit
sirna
duplex
requir
hydroxyl
group
phosphat
group
function
activ
commerci
synthesi
custom
sirna
present
avail
widespread
level
despit
eas
gener
chemic
synthes
sirna
key
consider
choos
appropri
sequenc
duplex
would
effect
silenc
mrna
transcript
whose
inhibit
desir
known
efficaci
silenc
vari
segment
transcript
target
present
clearcut
rule
exist
choos
best
segment
silenc
howev
suggest
target
region
least
nucleotid
away
translat
initi
site
transcript
au
gc
content
close
possibl
addit
sirna
target
code
sequenc
process
rnai
occur
cytoplasm
use
suggest
well
empir
test
varieti
experi
perform
chemic
presynthes
sirna
first
util
chemic
synthes
sirna
duplex
demonstr
effect
silenc
cytoskelet
protein
lamin
ac
lamin
nuclear
mitot
apparatu
protein
numa
vimentin
human
cell
line
suppress
specif
target
transcript
detect
mrna
protein
level
importantli
cellular
viabil
function
affect
silenc
procedur
subsequ
chemic
synthes
sirna
use
substitut
knockout
anim
chemic
inhibitor
enzymat
pathway
particular
relev
field
transplant
paper
hara
et
al
elucid
import
raptor
protein
mediat
signal
transduct
induc
rapamycin
target
rapamycin
tor
protein
sirna
specif
raptor
ad
toroverexpress
cell
downstream
signal
protein
abolish
addit
inhibit
biolog
pathway
chemic
synthes
sirna
extens
use
therapeut
vivo
experi
describ
later
section
problem
use
chemic
synthes
sirna
effect
target
sequenc
transcript
unpredict
howev
simultan
target
differ
segment
transcript
lead
effect
gene
silenc
exampl
target
hiv
entri
coreceptor
use
sever
sirna
duplex
differ
segment
mrna
transcript
result
higher
silenc
activ
use
sirna
singl
target
altern
simultan
use
sever
chemic
synthes
sirna
duplex
recent
present
sirna
duplex
everi
mrna
target
site
gener
enzymat
cleav
long
dsrna
homolog
target
gene
vitro
use
rnase
iii
extract
escherichia
coli
gener
long
doublestrand
sirna
typic
perform
vitro
transcript
target
gene
sens
antisens
use
rna
polymeras
promot
possess
advantag
earli
termin
wide
use
vitro
transcript
rna
almost
two
decad
multipl
sirna
approach
advantag
use
long
dsrna
silenc
without
induc
classic
nonspecif
panic
respons
although
interferon
product
report
one
group
use
enzymat
gener
sirna
despit
potenti
drawback
enzymat
gener
sirna
demonstr
induc
specif
potent
gene
silenc
recent
studi
target
exogen
puromycinresist
gene
endogen
express
hra
cjun
cfo
perform
advantag
enzymat
approach
rapid
effortless
identif
optim
sirna
speci
silenc
desir
biolog
function
chemic
synthes
sirna
possess
advantag
easi
manufactur
costli
addit
sequenc
select
difficult
owe
variabl
target
efficaci
owe
posit
effect
describ
earlier
abil
enzymat
gener
sirna
allow
cheaper
product
effect
genesilenc
abil
enzymat
gener
sirna
correspond
sequenc
overlap
entir
gene
inde
higher
silenc
abil
use
enzymat
gener
sirna
report
drawback
approach
spin
column
method
purif
must
use
separ
gener
sirna
contamin
uncleav
rna
duplex
residu
nucleic
acid
despit
opinion
author
enzymat
synthes
sirna
effect
conveni
method
induc
genesilenc
chemic
synthes
form
sever
variat
theme
made
order
improv
util
sirnamedi
genesilenc
techniqu
owe
doublestrand
featur
sirna
partial
palindrom
hairpin
loop
mrna
express
plasmid
stalk
portion
loop
would
hypothet
recogn
dsrna
cleav
sirna
dicer
approach
possess
sever
advantag
compar
administr
chemic
synthes
sirna
sirna
could
constitut
express
allow
higher
level
silenc
regulatori
element
could
ad
promot
region
plasmid
tissuespecif
silenc
occur
system
administ
plasmid
perman
gene
knockdown
cell
line
establish
vitro
work
gener
knockdown
anim
clone
rna
pol
iii
promot
caus
termin
second
uridin
transcript
form
mimic
sirna
natur
form
cleavag
long
dsrna
dicer
sirna
contain
two
symmetr
overhang
u
nucleotid
nt
necessari
genespecif
silenc
comparison
efficaci
tandem
hairpin
loop
express
sirna
suggest
stronger
vivo
silenc
efficaci
use
hairpin
approach
studi
kobayashi
et
al
small
interf
rna
specif
green
fluoresc
protein
gfp
plasmid
administ
mice
use
hydrodynam
method
transfect
superior
silenc
efficaci
longer
inhibitori
effect
observ
use
hairpin
express
sirna
compar
tandem
approach
novel
advanc
sirna
express
abil
select
activ
silenc
administr
exogen
agent
induc
sirnapromot
subsequ
optim
combin
rna
pol
iiielement
variou
commonli
use
repressor
system
exampl
tetracyclineinduc
plasmid
express
sirnasilenc
kinas
vivo
model
prostat
cancer
anticip
futur
develop
tissuespecif
promot
drive
sirna
express
occur
approach
would
allow
system
administr
sirnaexpress
plasmid
activ
desir
target
tissu
owe
timeconsum
process
clone
sirna
plasmidexpress
construct
need
verif
clone
sequenc
easier
approach
screen
sequenc
develop
method
involv
product
sirnaexpress
cassett
sec
basic
sec
consist
pcr
product
transcrib
form
rna
hairpin
loop
intracellularli
cleav
sirna
genespecif
sec
gener
seri
pcr
reaction
end
result
pcr
product
contain
pol
iii
promot
dna
sequenc
transcrib
form
hairpin
sirna
termin
sequenc
sec
design
restrict
site
possibl
clone
effect
sec
sequenc
express
plasmid
order
rais
larg
quantiti
sec
sec
techniqu
allow
perman
transfect
cell
sirna
expedi
low
cost
procedur
lend
mass
screen
sirna
librari
well
identif
sirna
target
site
recent
modif
sec
method
report
involv
gener
pcr
product
tandem
promot
drive
sirna
hairpin
loop
format
util
human
murin
promot
sens
antisens
nucleotid
transcrib
oppos
direct
templat
gener
duplex
sirna
dual
promot
vector
success
use
highthroughput
screen
cdna
librari
type
approach
use
identifi
novel
function
aspect
gene
without
priori
knowledg
specif
gene
variou
deliveri
method
develop
vitro
vivo
gene
silenc
origin
develop
transfect
protocol
sirna
use
liposomalbas
reagent
reagent
typic
allow
greater
transfect
efficaci
unfortun
costli
toxic
vivo
sever
method
induc
sirna
entri
cell
order
overcom
convent
drawback
describ
later
first
direct
deliveri
sirna
vivo
perform
use
hydrodynam
techniqu
administ
short
duplex
nake
sirna
larg
volum
salin
tail
vein
success
inhibit
gfp
hepat
surfac
antigen
b
achiev
observ
transfect
sirna
vivo
requir
liposom
base
transfect
reagent
suggest
nake
sirna
may
endocyt
pathway
entri
cell
demonstr
intranas
administr
nake
sirna
target
organprotect
enzym
heme
led
effect
gene
silenc
consequ
increas
ischemiareperfus
injuri
stabl
transfect
sirnaexpress
construct
perform
use
variou
type
viral
vector
approach
applic
retrovir
transfect
sirna
success
cell
line
primari
fibroblast
anoth
viral
approach
involv
use
adenovirus
adenovir
deliveri
sirna
effect
decreas
format
patholog
polyglutaminemedi
cellular
aggreg
murin
model
drawback
viral
approach
incorpor
depend
prolifer
target
cell
contrast
lentivir
vector
incorpor
great
efficaci
nondivid
cell
vitro
silenc
gfp
use
lentiviraldeliv
sirna
highli
effect
long
last
day
cultur
furthermor
lentivir
deliveri
sirna
capabl
inhibit
hiv
product
primari
human
cell
macrophag
vitro
vivo
administr
sirna
use
lentivir
vector
demonstr
gene
silenc
transgen
mice
although
previou
paper
transgen
mice
rat
gener
microinject
dna
construct
express
sirna
applic
sirna
drug
demonstr
recent
studi
therapeut
promis
sirna
fulfil
follow
condit
bioavail
lack
toxic
specif
silenc
effect
efficaci
vivo
appear
sirna
meet
criteria
origin
therapeut
indic
sirna
perform
vivo
use
viral
cancer
model
approach
appli
treatment
variou
diseas
tabl
small
interf
rna
success
treatment
viral
diseas
hiv
hepat
even
sever
acut
respiratori
syndrom
sar
associ
coronaviru
case
hiv
effect
silenc
primari
hiv
receptor
hiv
coreceptor
success
accomplish
sirna
result
prevent
viral
entri
target
cell
practic
util
block
hiv
entri
cell
could
transfect
hematopoiet
stem
cell
sirnaexpress
construct
progeni
cell
suscept
infect
approach
effect
render
monocyt
deriv
transfect
progenitor
resist
hiv
infect
induct
rnai
target
hepat
virus
perform
viral
infect
cell
line
addit
sirna
silenc
variou
portion
hepat
c
viru
genom
led
reduct
detect
viral
infect
cell
vivo
applic
sirna
demonstr
use
system
sirnaadministr
approach
mice
express
hepat
b
genom
liver
studi
demonstr
reduct
viral
mrna
viral
antigen
viral
genom
dna
liver
sera
sirna
recipi
addit
research
begun
explor
vitro
util
sirna
wide
varieti
virus
exampl
target
gene
human
papilloma
viru
possibl
induc
apoptosi
primari
patient
tumor
sampl
plasmiddriven
sirna
specif
influenza
west
nile
viru
effect
suppress
viral
transcript
infecti
virion
product
viral
infect
cell
line
use
cytotox
vero
cell
surrog
marker
sarsviru
infect
demonstr
transfect
sirna
abl
effect
inhibit
replic
coronaviru
subtyp
therefor
field
antivir
sirna
therapeut
aggress
studi
newli
develop
area
investig
sirna
mediat
precis
silenc
activ
use
block
express
aberrantli
express
mutat
protein
appeal
concept
lend
well
therapi
tumor
possess
wellknown
common
oncogen
featur
initi
vitro
studi
demonstr
effect
silenc
wide
varieti
mutat
oncogen
kra
mutat
bcrabl
appeal
sirnatarget
compar
convent
cytostat
drug
promis
cancerspecif
kill
absenc
collater
nonneoplast
cell
damag
concept
demonstr
observ
even
specif
chemic
gener
bcrabl
inhibitor
gleevec
also
possess
inhibitori
effect
nonleukem
hematopoiet
stem
cell
nonspecif
effect
anticip
sirnatarget
vivo
util
sirna
effect
perform
target
colorect
cancerassoci
gene
betacatenin
subsequ
sirnamedi
silenc
betacatenin
human
colon
cancer
cell
decreas
prolifer
diminish
invas
observ
addit
treat
cancer
cell
place
nude
mous
prolong
surviv
seen
compar
mice
receiv
unmanipul
tumor
similarli
silenc
oncogen
hra
led
inhibit
vivo
tumor
growth
human
ovarian
cancer
scid
mous
model
class
molecular
target
attract
field
oncolog
antiapoptot
famili
protein
small
interf
rna
inhibit
famili
member
associ
increas
suscept
prostat
cancer
chemotherapeut
intervent
thu
owe
overwhelm
amount
cancerspecif
gene
identifi
almost
daili
basi
util
sirna
elucid
gene
function
perhap
therapeut
intervent
becom
increasingli
import
discoveri
sirna
induc
genespecif
silenc
absenc
interferon
respons
global
protein
inhibit
come
attack
origin
paper
elshabir
et
al
demonstr
administr
chemic
synthes
sirna
lead
interferon
product
nonspecif
gene
inhibit
inde
author
hand
administr
sirna
elicit
effect
dendrit
cell
dc
one
sensit
cell
type
interferon
despit
sledz
et
al
recent
report
administr
sirna
induc
interferon
product
pkrdepend
mechan
sirna
administ
varieti
therapeut
usag
vivo
tabl
report
nonspecif
interferon
induct
toxic
publish
biolog
relev
find
evalu
anoth
group
report
certain
vector
util
deliveri
sirna
lead
similar
induct
interferon
respons
plausibl
scenario
plasmid
dna
may
caus
format
long
hairpin
rna
duplex
would
induc
pkr
one
possibl
explan
induct
interferon
respons
could
chemic
modif
end
sirna
scenario
propos
kim
et
al
demonstr
triphosph
duplex
play
critic
role
activ
pkr
case
develop
sirna
therapeut
ensur
duplex
evok
clinic
meaning
interferon
respons
respons
could
hypothet
lead
wide
varieti
toxic
human
studi
process
immun
modul
offer
plethora
molecular
target
sirna
silenc
molecul
lymphocyt
associ
activ
molecul
antigen
present
cell
apc
stimul
lymphocyt
solubl
molecular
signal
cytokin
molecul
associ
lymphocyt
extravas
home
effector
molecul
immun
complement
perforin
granzym
context
transplant
even
molecular
target
aris
gene
associ
ischemiareperfus
damag
gene
caus
apoptosi
transplant
organ
one
devast
immunemedi
patholog
bacteri
sepsi
mediat
system
releas
tnfa
util
sirna
silenc
gene
success
accomplish
murin
model
sepsi
addit
abil
sirna
modifi
immunolog
paramet
recent
demonstr
studi
leukocyt
adhes
flow
condit
tnfaactiv
human
umbil
cord
endotheli
cell
huvec
silenc
eselectin
activ
huvec
sirna
effect
wit
lack
mrna
transcript
inhibit
eselectin
protein
importantli
leukocyt
flow
activ
huvec
adher
sirna
treatment
dc
silenc
exhibit
higher
product
could
modul
immun
respons
antigenspecif
manner
vitro
vivo
small
interf
rnamedi
silenc
nfkb
subunit
use
gener
dc
possess
reduc
express
still
maintain
matur
abil
feasibl
inhibit
transcript
factor
dc
illustr
studi
silenc
ciita
transcript
factor
inhibit
mhc
express
also
block
product
plexin
structur
protein
endow
dc
dendrit
process
manipul
macrophag
peripher
blood
mononuclear
cell
cell
success
accomplish
sirna
find
combin
demonstr
pharmacolog
activ
sirna
rais
prospect
use
sirna
immun
suppress
previou
approach
suppress
tcell
respons
includ
administr
drug
eg
cyclosporin
antibodi
eg
fusion
protein
eg
unfortun
strategi
possess
signific
drawback
organotox
lack
specif
increas
thromboembol
poor
pharmacokinet
base
previou
therapeut
util
sirna
accomplish
wide
varieti
gene
silenc
therapeut
anticip
silenc
immunolog
gene
cell
feasibl
practic
altern
tradit
immun
suppress
although
earlier
studi
rais
concern
inhibitori
effect
rnai
may
dilut
prolifer
cell
administr
duplex
sirna
recent
studi
use
plasmiddriven
lentiviraldeliv
sirna
suffer
drawback
immunolog
attack
graft
organ
initi
mediat
tcell
respons
inhibit
cellular
target
would
requir
identif
master
regul
gene
control
plethora
downstream
biolog
cascad
molecular
target
cell
limit
antibodi
inhibit
extracellular
protein
wherea
pharmacolog
inhibitor
often
possess
lack
specif
target
specif
receptor
subunit
someth
difficult
perform
antibodi
perform
sirna
one
target
would
cytokin
receptor
common
gamma
chain
knockout
mice
whose
cell
defici
protein
allow
perman
surviv
islet
allograft
anoth
class
target
would
particularli
attract
transplant
transcript
factor
associ
tcell
inflammatori
respons
exampl
signal
transduc
activ
transcript
stat
dnabind
protein
implic
activ
inflammatori
tcell
respons
relev
target
protein
contrast
specif
cytokin
seen
experi
ifnc
knockout
recipi
possess
similar
acceler
rate
allograft
reject
wildtyp
mice
wherea
knockout
recipi
signific
decreas
graft
patholog
prolong
allograft
accept
ad
attract
target
would
endow
cell
increas
predisposit
induct
toler
elegantli
demonstr
zhou
et
al
knockout
mice
tbet
anoth
inflammatoryassoci
transcript
factor
whose
absenc
result
defici
develop
silenc
gene
may
yield
result
compar
inhibit
transplant
small
interf
rna
may
also
use
genesilenc
apc
side
immun
respons
previou
report
use
ao
demonstr
inhibit
costimulatori
molecul
dc
prolong
allograft
surviv
addit
administr
dc
induc
antigenspecif
toler
gener
treg
cell
therefor
target
costimulatori
molecul
apc
use
sirna
appear
potenti
fruit
approach
state
previous
transcript
factor
nfjb
possess
potent
immun
stimulatori
activ
abil
activ
sever
signal
pathway
apc
lead
robust
tcell
stimul
feasibl
silenc
nfjb
subunit
alreadi
demonstr
result
gener
dc
owe
potent
tolerogen
activ
nfjb
inhibitor
anticip
sirna
silenc
target
would
use
approach
induc
apcmedi
toler
cytokin
elabor
apc
involv
induct
tcell
differenti
would
also
promis
target
previous
demonstr
silenc
dc
induc
deviat
vitro
vivo
futur
studi
evalu
potent
induc
promis
sirnatherapeut
held
back
question
deliveri
although
viral
vector
promis
preclin
model
fatal
report
clinic
trial
gene
therapi
use
vector
place
signific
roadblock
implement
viral
approach
murin
studi
indic
sirna
administ
hydrodynam
approach
howev
strategi
would
clearli
ethic
clinic
one
attract
method
deliveri
sirna
use
cellspecif
immunoliposom
immunoliposom
artifici
model
membran
specif
antibodi
attach
outer
lipid
leaflet
thu
enabl
specif
discharg
liposom
content
cell
express
surfac
antigen
recogn
respect
antibodi
attract
approach
uniqu
cellular
specif
achiev
util
liposom
techniqu
demonstr
clinic
studi
liposom
drug
allow
much
lower
administr
said
drug
without
lose
desir
therapeut
effect
approach
success
use
target
chemotherapeut
agent
tumor
use
antibodi
oncogen
protein
abil
immunoliposom
deliv
nucleic
acid
specif
target
cell
recent
demonstr
addit
vivo
deliveri
sirna
previous
report
use
liposom
type
liposom
current
use
cellspecif
target
polyethelen
glycol
peg
immunoliposom
nucleic
acid
entrap
fluid
phase
liposom
antibodi
coupl
peg
anchor
lipid
bilay
immunoliposom
demonstr
innocu
varieti
vivo
toxicolog
model
specif
transplant
one
could
use
immunoliposom
specif
target
sirna
th
cell
via
apc
dc
use
macrophag
use
stealth
liposom
anoth
area
sirna
applic
form
organstorag
solut
donor
organ
subject
flush
storag
hypotherm
condit
c
special
formul
solut
organ
storag
solut
order
wash
debri
decreas
damag
transport
varieti
group
perform
modif
typic
perfus
solut
attain
better
graft
function
despit
modif
littl
work
perform
alter
organ
tissu
immunogen
directli
relat
graft
reject
chen
et
al
transfect
kidney
nake
antisens
dna
order
suppress
express
intracellular
adhes
success
prevent
reperfus
injuri
note
similarli
suppress
nfjb
activ
report
rat
heart
administr
decoy
oligonucleotid
organ
perfus
solut
previou
attempt
modifi
direct
antigen
present
donor
dc
use
monoclon
antibodi
fail
owe
inabl
perfus
process
deliv
antibodi
suffici
number
target
cell
addit
sirnatarget
gene
associ
immun
reject
endotheli
activ
apoptosi
organ
storag
solut
potenti
use
avenu
ex
vivo
administr
sirna
support
approach
studi
demonstr
effici
genesilenc
sirna
administr
whole
kidney
cultur
observ
intranas
deliveri
sirna
lead
pulmonari
gene
silenc
also
strengthen
notion
sirna
use
local
gene
silenc
isol
organ
discoveri
rnai
open
door
genespecif
manipul
safe
physiolog
use
manner
silenc
gene
express
sirna
superior
convent
geneor
antibodyblock
approach
owe
follow
block
efficaci
potent
target
gene
express
specif
inhibitori
effect
pass
multipl
gener
vitro
transfect
efficaci
higher
express
stabl
manner
vivo
use
practic
safer
owe
lower
concentr
need
therapeut
effect
tissueor
cellspecif
gene
target
possibl
use
specif
promot
vector
specif
antibodi
conjug
liposom
simultan
target
multipl
gene
multipl
exon
possibl
increas
efficaci
anticip
discoveri
new
physiolog
target
match
specif
potent
sirna
strategi
lead
overal
improv
graft
surviv
recipi
organ
transplant
